Form 4: Pharvaris CEO Berndt Modig Executes Stock Sale

Pharvaris N.V. CEO Berndt Modig sold 2,292 shares of common stock on May 18, 2026, pursuant to a Rule 10b5-1 trading plan.

Summary

• CEO Berndt Modig sold 2,292 shares of Pharvaris N.V. common stock.
• The transaction occurred on May 18, 2026, at a weighted average price of $29.222 per share.
• The sale was executed under a pre-established Rule 10b5-1 trading plan.
• Following the transaction, the CEO retains beneficial ownership of 137,500 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard practice for corporate executives.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the CEO's direct equity stake in the company.

Risks

• Market perception of insider selling can sometimes lead to short-term volatility in share price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are routine in the biotechnology sector, often used for tax planning or liquidity purposes rather than signaling a lack of confidence in company prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the CEO's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Berndt Modig, Biotech